Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Genia Long

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Health Affairs (Project Hope)|May 5, 2025
Oncology Drugs: The Authors ReplyHenry Grabowski, Joseph A DiMasi, Genia Long
Health Affairs (Project Hope)|October 7, 2024
Postapproval Innovation For Oncology Drugs And The Inflation Reduction ActHenry Grabowski, Joseph A DiMasi, Genia Long
Journal of Medical Economics|April 12, 2016
Updated trends in US brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer, et al.
Journal of Medical Economics|July 13, 2021
Continuing trends in U.S. brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer, et al.
Health Affairs (Project Hope)|February 4, 2015
The roles of patents and research and development incentives in biopharmaceutical innovationHenry G Grabowski, Joseph A DiMasi, Genia Long
The American Journal of Managed Care|December 21, 2017
Insurance switching and mismatch between the costs and benefits of new technologiesDavid Cutler, Michael Ciarametaro, Genia Long, et al.
Journal of Health Politics, Policy and Law|May 6, 2011
Commercial importation of prescription drugs in the United States: short-run implicationsPatricia M Danzon, Scott J Johnson, Genia Long, et al.
Expert Review of Clinical Pharmacology|October 24, 2013
Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copiesAnna Kaltenboeck, Genia Long, Eleanor Hayes-Larson, et al.
Health Affairs (Project Hope)|November 10, 2011
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman ActHenry G Grabowski, Margaret Kyle, Richard Mortimer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 3, 2025
The Impact of the Inflation Reduction Act's Drug Price Negotiation Program on Incentives for Clinical Development of New DrugsRobert J Nordyke, Julie A Patterson, James Motyka, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Health Affairs (Project Hope)|May 5, 2025
Oncology Drugs: The Authors ReplyHenry Grabowski, Joseph A DiMasi, Genia Long
Health Affairs (Project Hope)|October 7, 2024
Postapproval Innovation For Oncology Drugs And The Inflation Reduction ActHenry Grabowski, Joseph A DiMasi, Genia Long
Journal of Medical Economics|April 12, 2016
Updated trends in US brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer, et al.
Journal of Medical Economics|July 13, 2021
Continuing trends in U.S. brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer, et al.
Health Affairs (Project Hope)|February 4, 2015
The roles of patents and research and development incentives in biopharmaceutical innovationHenry G Grabowski, Joseph A DiMasi, Genia Long
The American Journal of Managed Care|December 21, 2017
Insurance switching and mismatch between the costs and benefits of new technologiesDavid Cutler, Michael Ciarametaro, Genia Long, et al.
Journal of Health Politics, Policy and Law|May 6, 2011
Commercial importation of prescription drugs in the United States: short-run implicationsPatricia M Danzon, Scott J Johnson, Genia Long, et al.
Expert Review of Clinical Pharmacology|October 24, 2013
Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copiesAnna Kaltenboeck, Genia Long, Eleanor Hayes-Larson, et al.
Health Affairs (Project Hope)|November 10, 2011
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman ActHenry G Grabowski, Margaret Kyle, Richard Mortimer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 3, 2025
The Impact of the Inflation Reduction Act's Drug Price Negotiation Program on Incentives for Clinical Development of New DrugsRobert J Nordyke, Julie A Patterson, James Motyka, et al.
Pageof 3